Hypertrophic obstructive cardiomyopathy and mitral valve abnormalities

Nelis Asan¹, E. Apetrei¹², D. Deleanu¹, V. A. Iliescu¹², I. M. Coman¹²

Article received on the 6th of February 2013. Article accepted on the 24th of February 2013.

Contact address:
Prof. Dr. Eduard Apetrei, “Prof. Dr. CC. Iliescu” Institute of Emergency for Cardiovascular Diseases, Bucharest, 258 Fundeni Street, District number 2.
E-mail: eapetrei@gmail.com

Abstract: Hypertrophic obstructive cardiomyopathy is a fascinating disease entity and a source of controversy since the first modern descriptions by Brock in 1957². Recognition and understanding the significance of left ventricle outflow obstruction has indeed been a “winding road”, but one that has eventually provided clinically relevant answers directly related to patient management. We report a case of hypertrophic obstructive cardiomyopathy (resting left ventricular outflow tract gradient of 136 mmHg) and mitral valve abnormalities in a 63 year-old woman.

Case Study

A 63 year-old woman presented with fatigue and progressive shortness of breath on exertion (class III NYHA). The patient reported remained asymptomatic until age 55, when she was diagnosed with severe subaortic stenosis. Transthoracic echocardiography, at that time, showed left ventricle (LV) hypertrophy – intraventricular septum (IVS) 13 mm and LV posterior wall (PP) 13 mm, LV outflow tract gradient of 107/43 mmHg, mitral regurgitation grade I-II and 50% ejection fraction (EF). There is no any data available related with the morphology of aortic or mitral valve. The patient had several cardiovascular risk factors, such as 6-year history of moderate hypertension, dyslipidemia, 6-year history of diabetes mellitus type II treated with oral antidiabetic agents and family history of sudden cardiac arrest (father died of sudden cardiac arrest when he was 65 years). She followed the treatment as prescribed in 2005 with betablockers and non-dihydropyridine calcium channel blocker and had a favorable clinical evolution. Over a period of 3 months, the patient readmitted to the hospital because of dyspnea on minimal-moderate exertion. Clinical examination revealed stable patient with a blood pressure of 120/70 mmHg, pulse rate of 80 bpm, the first sound is soft at the apex, the second sound is normal, mydsistolic ejection murmur heard best at third left parasternal space and at apex, increased in orthostatism; without systemic or pulmonary congestion signs. The electrocardiogram (Figure 1) indicated sinus rhythm 70bpm, QRS axis +20 grade, left ventricle hypertrophy, ST segment depression 3.5 mm with negative T wave in V4-V6, DI, DII and aVL. Chest X-ray showed slight enlargement of the heart silhouette with cardiothoracic ratio of 55% and mild accentuation of pulmonary arterial vessels.

Transthoracic echocardiography (TTE) showed that the interventricular septum and LV posterior wall are thickened (Figure 3), left ventricular outflow tract peak gradient (Figures 4 and 7), intrinsic abnormalities of the mitral valve – direct papillary insertion into the anterior mitral leaflet and a particular structure of interventricular septum (Figure 5)

In Figure 3, two dimensional TTE long axis plane identified left ventricle (LV) with end-diastolic diameter 37mm, end-systolic diameter 20mm, left atrium diameter 43mm, left ventricular hypertrophy – IVS 21mm at base and 17mm at middle, PP 13mm. The thickness of the anterior wall of the right ventricle is 7mm.

Left ventricular outflow tract obstruction is showed in Figure 4 and Figure 7. Continuous-wave (CW)
Doppler in apical 5 chambers recorded a left ventricular outflow tract peak gradient of 138 mmHg (Figure 7).

The anomalies of mitral subvalvular apparatus include (Figure 3 and Figure 5) nodular calcifications on anterior mitral valve chordae, thickening chordae, anomalous papillary muscle with direct insertion into the anterior mitral leaflet. Aortic valve are thickening and stiffness (calcification), but with normal leaflet mobility. Tricuspid and pulmonary valves are normal. Color Doppler shows high velocities across the left ventricular outflow tract in mosaic color and mitral regurgitation within the left atrium (green arrow).

Assessment of LV diastolic function – mitral inflow shows a restrictive inflow pattern. LV systolic function is normal with a LV ejection fraction of 65%.

Particularly is the structure of interventricular septum (Figure 5). In long axis plane, we observed 2 thickening trabeculae 4mm-5mm inserting into LV free wall at apex and into the interventricular septum.
Hypertrophic obstructive cardiomyopathy and mitral valve abnormalities

Other anomalies of mitral subvalvular apparatus include abnormal chordae tendineae that attach to the ventricular septum or left ventricular free wall and accessory papillary muscles, all which may tether the mitral leaflets toward the septum and produce LVOT obstruction.

The choice of optimal procedure must be individualized based on age, comorbidities, suitability of coronary anatomy, intrinsic mitral valve disease, patient preference, and operator experience.

The conventional septal myectomy (Marrow procedure) is not the optimal procedure.

After the classic septal myectomy, the patients with HOCM and anomalies of the mitral subvalvular apparatus can lead to intraoperative death, incomplete or only temporary relief of LVOT obstruction, persistent of SAM and mitral regurgitation.

Additional procedures are represented by: anterior mitral leaflet excision or plicating, "false chordae" excision and papillary muscle realignment.

Rankin J at al. described a new surgical concept: septal myectomy, excision of papillary muscle incriminated in LVOT obstruction, chordae excision and mitral ring anuloplasty; the mitral valve was repaired by connecting the left aspect of the leaflets to the posterior papillary muscle, using Gore-Tex artificial chords.

Mitral valve replacement is possible in mitral regurgitation associated with chordae rupture, mitral valve prolapse, mitral ring dilatation or in valvular morphological disease like restricted, thickened, calcifications or myxomatous valve.

In conclusion, we reported a patient with obstructive hypertrophic cardiomyopathy (LVOT peak gradient of 138 mmHg on transthoracic echocardiography and 96 mmHg on left ventricular catheterization) and severe mitral regurgitation of III-IV grade. A spectrum of mitral leaflet abnormalities and systolic displacement of mitral anterior leaflet and subvalvular apparatus have been related to the mechanism of mitral regurgitation.

The patient is at increased risk for sudden death (SCD). We have identified 2 risk factors for SCD: LV septal hypertrophy and family history of sudden death. Three members of family (the daughter and 2 nephew) were evaluated or screened with ECG and echocardiography, which were normal. In our case report, percutaneous alcohol septal ablation, method we perform currently in our institute, is constrained by mitral valve abnormalities. The myectomy has the advantage of direct visualization of complex LV outflow tract anatomy.
and recognition of all structural abnormalities that contribute to mechanical subaortic obstruction.

European Society of Cardiology and American College of Cardiology recommend surgical septal myectomy as the gold standard treatment for most drug-refractory and severely symptomatic HOCM patients. However, in Europe after the introduction of alcohol septal ablation 15-20 years ago, septal myectomy has essentially disappeared, alcohol septal ablation being promoted as a superior and easier treatment strategy for decrease or abolition of the LVOT obstruction.

Surgical myectomy is performed in only 5 European centres (3 in Italy). Recent the Italian – Bergamo Center published a report about 124 patients with obstructive HCM and heart failure symptoms who underwent myectomy. The LV outflow gradient decreased from 95 ± 36 mmHg before surgery to 12 ± 6 mmHg post surgery. Periprocedural mortality was 0.8% (1 patient) and 0.8%, 3.3% at 1 and 5 years respectively. The study of Iacovoni et al. has important implications for the management of obstructive HCM in Europe and should be a stimulus for other institutions elsewhere in Europe to initiate HCM programmes.

Conflict of interests: The authors declare that no conflict of interest exists.

References